COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE VS ALENDRONATE MONOTHERAPY FOR THE PREVENTION OF FRACTURES IN POSTMENOPAUSAL US WOMEN AT INCREASED RISK OF FRACTURE

被引：0
|
作者：
Hiligsmann, M. [1 ]
Williams, S. [2 ]
Fitzpatrick, L. [2 ]
Silverman, S. [3 ]
Weiss, R. J. [2 ]
Reginster, J. Y. [4 ]
机构：
[1] Maastricht Univ, Maastricht, Netherlands
[2] Radius Hlth Inc, Waltham, MA USA
[3] Univ Calif Los Angeles, Med Ctr, Cedars Sinai, Beverly Hills, CA USA
[4] Univ Liege, Liege, Belgium
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1136
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS26
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan
    Mori, Takahiro
    Crandall, Carolyn J.
    Fuji, Tomoko
    Ganz, David A.
    ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)
  • [22] Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures
    Hiligsmann, Mickael
    Silverman, Stuart L.
    Singer, Andrea J.
    Pearman, Leny
    Wang, Yamei
    Caminis, John
    Reginster, Jean-Yves
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 (01)
  • [23] Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures
    Mickael Hiligsmann
    Stuart L. Silverman
    Andrea J. Singer
    Leny Pearman
    Yamei Wang
    John Caminis
    Jean-Yves Reginster
    Aging Clinical and Experimental Research, 36
  • [24] Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women
    Schousboe, JT
    Nyman, JA
    Kane, RL
    Ensrud, KE
    ANNALS OF INTERNAL MEDICINE, 2005, 142 (09) : 734 - 741
  • [25] Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
    Lane, Nancy
    Weiss, Richard
    Mitlak, Bruce
    Wang, Yamei
    Valenzuela, Guillermo
    Deal, Chad
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [26] COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
    Hiligsmann, Mickael
    Reginster, Jean-Yves
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 112 - 113
  • [27] COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH GENERIC ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
    Hiligsmann, M.
    Reginster, J. Y.
    VALUE IN HEALTH, 2010, 13 (07) : A309 - A310
  • [28] COST-EFFECTIVENESS OF ALENDRONATE THERAPY FOR OSTEOPENIC POSTMENOPAUSAL WOMEN IN JAPAN
    Moriwaki, K.
    Komaba, H.
    Noto, S.
    Yanagisawa, S.
    Inoue, H.
    Takeshi, T.
    Fukagawa, M.
    Takahashi, H. E.
    VALUE IN HEALTH, 2012, 15 (04) : A46 - A47
  • [29] COST-EFFECTIVENESS OF ABALOPARATIDE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Hiligsmann, M.
    Williams, S. A.
    Fitzpatrick, L. A.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S50 - S51
  • [30] COST-EFFECTIVENESS OF ABALOPARATIDE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Hansson-Hedblom, A.
    Geale, K.
    Borgstrom, F.
    Johansson, H.
    Fitzpatrick, L.
    Kanis, J. A.
    VALUE IN HEALTH, 2018, 21 : S197 - S197
12345